KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Total Debt (2016 - 2025)

Inovio Pharmaceuticals' Total Debt history spans 16 years, with the latest figure at $50.4 million for Q3 2025.

  • For Q3 2025, Total Debt changed N/A year-over-year to $50.4 million; the TTM value through Sep 2025 reached $50.4 million, changed N/A, while the annual FY2024 figure was $13.3 million, 20.96% down from the prior year.
  • Total Debt for Q3 2025 was $50.4 million at Inovio Pharmaceuticals, up from $11.4 million in the prior quarter.
  • Across five years, Total Debt topped out at $50.4 million in Q3 2025 and bottomed at $491645.0 in Q3 2021.
  • The 5-year median for Total Debt is $1.8 million (2021), against an average of $9.6 million.
  • The largest annual shift saw Total Debt tumbled 38.15% in 2021 before it soared 1148.11% in 2023.
  • A 5-year view of Total Debt shows it stood at $548032.0 in 2021, then skyrocketed by 198.12% to $1.6 million in 2022, then surged by 926.49% to $16.8 million in 2023, then decreased by 20.96% to $13.3 million in 2024, then soared by 280.11% to $50.4 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Total Debt are $50.4 million (Q3 2025), $11.4 million (Q2 2025), and $9.5 million (Q1 2025).